CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
EBOVAC 2 aims to assess the safety and effectiveness of two Ebola vaccines through extensive clinical trials in Europe and Africa. The project includes studies on immune responses and special populations, while enhancing local research capacities and sharing findings with stakeholders.
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.This will be done by:1.
Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4)2.
Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of appr…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Bordeaux
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Talence
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Creteil
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
